People taking an oral formulation of the glucagon-like peptide-1 (GLP-1) agonist semaglutide were 14% less likely than those taking a placebo to experience cardiovascular death, heart attack or stroke ...

People should take blood pressure tablets ... cardiovascular system. But questions remain around the timing of blood pressure medication, with some experts saying people should take their medicine ...

“The same cardiovascular benefits can be derived from the tablet that we’ve seen from the injectables ... in the study that ...

Novo Nordisk has submitted a supplemental application to the FDA for Rybelsus 14 mg to lower cardiovascular risk in adults with type 2 diabetes. A regulatory decision is anticipated in 2025.

The benefits of naltrexone/bupropion (Mysimba) continue to outweigh its risks, despite ongoing uncertainty about long-term ...